Chiasma Announces New Data for Investigational Octreotide Capsules
Two studies presented at ENDO 2015 contribute to growing body of
knowledge about acromegaly treatment
Newton, Mass. and Jerusalem, Israel, March 5, 2015 – Chiasma, Inc., a U.S. privately-held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies. To Read More Download PDF below.